# Gastric mucosal repair by Men’s Huwei Powder via EGF-NO/PGE2-PI3K-TLR4 in RELISH: Restoring Equilibrium through long-term integration of synergistic health

**Authors:** Kaijie Xu, Jing Li, Shoupeng Guo, Jin Zhang, Xichun Zhang

PMC · DOI: 10.3389/fphar.2025.1594089 · Frontiers in Pharmacology · 2025-07-11

## TL;DR

Men's Huwei Powder, a Traditional Chinese Medicine, helps repair stomach lining by balancing inflammation and gut microbes, offering a holistic treatment for gastric injury.

## Contribution

MHWP demonstrates a novel, multi-targeted mechanism for gastric mucosal repair via EGF-NO/PGE2 and microbiota modulation under the RELISH framework.

## Key findings

- MHWP activates the EGF–NO/PGE2 axis and suppresses pro-inflammatory pathways in gastric tissue.
- MHWP modulates gut microbiota, including Ligilactobacillus and Lachnospiraceae:CAG_95, to aid mucosal repair.
- Bioactive metabolites like 6-gingerol and atractylenolide II contribute to MHWP's therapeutic effects.

## Abstract

Gastric mucosal injury (GMI) involves inflammation, oxidative stress, and barrier dysfunction. Existing therapies offer limited efficacy with side effects. Men's Huwei Powder (MHWP), a Traditional Chinese Medicine (TCM) formula developed under the RELISH (Restoring Equilibrium through Long-term Integration of Synergistic Health) framework, aims to restore mucosal and systemic equilibrium.

The experiment was grouped using a uniform design, followed by the construction of an ethanol-induced GMI rat model. The effects of MHWP were assessed through histological examination, ELISA, RT-PCR, 16S rRNA sequencing, and LC-MS-based serum fingerprint analysis. Multivariate modeling techniques, including SPRA, PLSR, and pSEM, were utilized to explore the comprehensive regulatory mechanisms of MHWP.

MHWP promotes activation of the EGF–NO/PGE2 axis and concurrently suppresses key nodes of the PI3K/Akt/NF-κB signaling pathway, leading to downregulation of pro-inflammatory cytokines—including IL-1β, IL-6, and TNF-α—in both serum and gastric tissue. Beyond its localized effects, MHWP exerts systemic benefits by inhibiting hepatic TLR4, MyD88, and NF-κB expression, thereby reducing liver-derived IL-6 and TNF-α and ameliorating ethanol-induced liver injury. This hepatic protection contributes to improved gastric mucosal healing and systemic inflammatory balance. Gut microbiota profiling identified key genera—such as Ligilactobacillus, Acutalibacter, and Lachnospiraceae:CAG_95—as critical mediators of mucosal repair, with MHWP modulating their abundance in a botanicals–dependent manner. These genera were closely linked to the regulation of NO, COX-2, and gastric IL-1β and IL-6, highlighting their critical role in the EGF–NO/PGE2 axis and inflammatory signaling. Serum HPLC fingerprinting identified several bioactive metabolites—including 6-gingerol (P1), atractylenolide II (P10), and dihydrostilbene base + 3O,2Prenyl (P18)—as major contributors to MHWP's efficacy. Closely associated with specific botanical drugs, these metabolites synergistically regulated multiple inflammatory and reparative pathways, underscoring MHWP's holistic therapeutic mechanism.

MHWP exerts multi-targeted effects through integrated modulation of the liver, gut microbiota, and serum metabolites. These findings underscore its potential as a holistic and sustainable TCM-based intervention for GMI, in alignment with the RELISH framework.

## Linked entities

- **Genes:** EGF (epidermal growth factor) [NCBI Gene 1950], Nos1 (nitric oxide synthase 1, neuronal) [NCBI Gene 18125], ptges2.L (prostaglandin E synthase 2 L homeolog) [NCBI Gene 100037123], PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290], TLR4 (toll like receptor 4) [NCBI Gene 7099], IL1B (interleukin 1 beta) [NCBI Gene 3553], IL6 (interleukin 6) [NCBI Gene 3569], TNF (tumor necrosis factor) [NCBI Gene 7124], MYD88 (MYD88 innate immune signal transduction adaptor) [NCBI Gene 4615], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790], COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513]
- **Chemicals:** 6-gingerol (PubChem CID 3473), dihydrostilbene base + 3O,2Prenyl (PubChem CID 637247)
- **Species:** Ligilactobacillus (taxon 2767887), Acutalibacter (taxon 1918385)

## Full-text entities

- **Genes:** TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, MYD88 (MYD88 innate immune signal transduction adaptor) [NCBI Gene 4615] {aka IMD68, MYD88D, WM1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}
- **Diseases:** GMI (MESH:D013272), inflammation (MESH:D007249), liver injury (MESH:D017093)
- **Chemicals:** PGE2 (MESH:D015232), atractylenolide II (MESH:C458582), P1 (MESH:C480041), NO (MESH:D009614), ethanol (MESH:D000431), 6-gingerol (MESH:C007845), 3O,2Prenyl (-)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12289676/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12289676/full.md

## References

62 references — full list in the complete paper: https://tomesphere.com/paper/PMC12289676/full.md

---
Source: https://tomesphere.com/paper/PMC12289676